Form 4: Assembly Biosciences Director Alexander Schornstein Increases Stake Through Open Market Purchases

Director Alexander Schornstein of Assembly Biosciences, Inc. has increased his holdings through open market purchases of common stock.

Summary

• Alexander Schornstein, a director at Assembly Biosciences, Inc., has acquired additional shares of the company's common stock through open market purchases.
• On November 22, 2024, Mr. Schornstein purchased 17,024 shares at a weighted average price of $14.8675.
• On November 25, 2024, he made two further purchases, acquiring 2,976 shares at $15.00 and 5,000 shares at a weighted average price of $14.85.
• These transactions increased his total direct holdings to 728,113 shares.

Sentiment

Score: 7

Explanation: The document reflects positive sentiment due to the director's increased investment in the company, suggesting confidence in its future.

Positives

• The director's open market purchases signal confidence in the company's future prospects.
• The increased stake demonstrates a commitment to the company's success.

Industry Context

Insider buying is often seen as a positive sign by investors, suggesting that those with the most knowledge of the company's prospects are optimistic about its future.

Comparison to Industry Standards

• It is common for directors to purchase shares in their own companies, but the size and frequency of these purchases can be an indicator of their confidence.
• Compared to other biotech companies, this level of insider buying is a positive signal, but it is important to consider the overall context of the company's performance and industry trends.

Stakeholder Impact

• The increased stake by a director may positively influence shareholder confidence.
• The purchases do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

insider trading, share purchase, open market, common stock, director, Assembly Biosciences, ASMB, Alexander Schornstein